藥明生物(02269.HK)年度純利升67.5%至16.93億元 未完成訂單總量大增122%
格隆匯 3 月 23日丨藥明生物(02269.HK)公佈年度業績,截至2020年12月31日止12個月,公司收益為人民幣56.12億元,同比增長40.9%;毛利為人民幣25.33億元,同比增長52.7%;純利為人民幣16.93億元,同比增長67.5%;經調整純利為人民幣17.16億元,同比增長42.8%;每股盈利為人民幣0.43元。
集團未完成訂單總量(包括未完成服務訂單及未完成潛在里程碑付款)亦由2019年12月31日的51.02億美元大幅增長122.0%至2020年12月31日的113.24億美元,其中未完成服務訂單由16.86億美元增長293.2%至66.29億美元,而未完成潛在里程碑付款由34.16億美元增長37.4%至46.95億美元。未完成服務訂單指集團已簽約但尚未提供服務的收益金額。未完成潛在里程碑付款指本集團已簽約但尚未履行且未收取款項的潛在里程碑付款總額。此里程碑收入需要更長時間才能在開發的各個不同階段實現收費,同時也受制於項目成功率及項目進展等本集團可能無法完全控制的因素的影響。
集團在報吿期內亦進一步開拓客户,並與全球20大製藥公司中的14家及中國50大製藥公司中的32家開展合作。截至2020年12月31日止年度,集團為369名客户提供服務,而去年則為266名客户。集團相信,持續擴張能力和規模以及與現有客户深化合作可進一步提高其價值鏈並讓集團繼續牢牢地把握未來不斷增長的市場機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.